Mesoblast shows signs of revenue acceleration with 2026Q4 revenue reaching $35.0M, driven primarily by milestone payments from remestemcel-L, but profitability remains elusive as operating losses widened to -$20.5M and R&D costs consumed 73% of revenue. The ba...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 26, 2026 | -$0.13-23.2% vs -$0.11 | $69M+28.0% vs $54M |
Q2 2026 Apr 30, 2026 | -$0.07+11.7% vs -$0.08 | $34M+18.0% vs $29M |
Q1 2026 Feb 26, 2026 | -$0.31-31.2% vs -$0.24 | $51M-3.2% vs $53M |
Q4 2025 Sep 3, 2025 | -$0.21+43.0% vs -$0.37 | $7M-77.1% vs $31M |
Biogen (NASDAQ: BIIB - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 87.9% of Biogen shares are held
Mesoblast Limited (NASDAQ: MESO - Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $15.87 and traded as high as $17.29. Mesoblast shares last traded at $17.14, with a volume of 86,062 shares. Analyst Upgrades and Downgrades A number of
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026.
Benchmark MESO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mesoblast Limited (MESO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.29 | $1.98B | -18.20 | 191.39% | -593.92% | -18.95% | — | |
| $2.43 | $283.24M | -2.11 | -51.24% | -1941.09% | -65.08% | — | |
| $4.77 | $695.28M | 14.91 | 19.99% | 1.76% | 2.61% | — | |
| $20.38 | $272.68M | -26.81 | -5.91% | -3.14% | -2.7% | — | |
| $184.53 | $10.41B | 214.57 | 16.36% | 5.29% | 1.98% | — | |
| $65.81 | $8.19B | -10.06 | 376.56% | -1259.87% | — | — |
Mesoblast Limited (MESO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MESO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mesoblast Limited (MESO) stock FAQ — growth, dividends, profitability & financials explained
Mesoblast Limited (MESO) reported $50.6M in revenue for fiscal year 2025. This represents a 9964% increase from $0.5M in 2005.
Mesoblast Limited (MESO) grew revenue by 191.4% over the past year. This is strong growth.
Mesoblast Limited (MESO) reported a net loss of $86.8M for fiscal year 2025.
Mesoblast Limited (MESO) has a return on equity (ROE) of -19.0%. Negative ROE indicates the company is unprofitable.
Mesoblast Limited (MESO) had negative free cash flow of $45.1M in fiscal year 2025, likely due to heavy capital investments.
